A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol consumed when someone on the drug does drink

The new findings add to growing evidence that the medicines could help people with alcohol addiction. View on euronews

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

Weight loss drugs may also help reduce alcohol cravings, according to a new study. But you shouldn't use them to help curb drinking habits just yet.

A new study published in the JAMA Psychiatry gives the strongest evidence that semaglutide — the active ingredient in Ozempic and the weight-loss drug Wegovy — could genuinely help individuals struggling with alcohol addiction drink less and crave alcohol less frequently.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol cravings and consumption.

A new study suggests that using weight loss drugs such as Ozempic and Wegovy can lead to less alcohol consumption. The study, published Wednesday by JAMA Psychiatry, looked into 48 people the

Weight-loss injections slash alcohol cravings and curb heavy drinking by almost half, new research revealed. The JAMA Psychiatry study showed a weekly jab of semaglutide, also known as brand names Ozempic and Wegovy, cut the amount people drink in a day by about 40 per cent.